Back to Search Start Over

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study.

Authors :
Wong, Raimond KW
Wong, Raimond KW
Deshmukh, Snehal
Wyatt, Gwen
Sagar, Stephen
Singh, Anurag K
Sultanem, Khalil
Nguyen-Tân, Phuc F
Yom, Sue S
Cardinale, Joseph
Yao, Min
Hodson, Ian
Matthiesen, Chance L
Suh, John
Thakrar, Harish
Pugh, Stephanie L
Berk, Lawrence
Wong, Raimond KW
Wong, Raimond KW
Deshmukh, Snehal
Wyatt, Gwen
Sagar, Stephen
Singh, Anurag K
Sultanem, Khalil
Nguyen-Tân, Phuc F
Yom, Sue S
Cardinale, Joseph
Yao, Min
Hodson, Ian
Matthiesen, Chance L
Suh, John
Thakrar, Harish
Pugh, Stephanie L
Berk, Lawrence
Source :
International journal of radiation oncology, biology, physics; vol 92, iss 2, 220-227; 0360-3016
Publication Year :
2015

Abstract

Purpose and objectivesThis report presents the analysis of the RTOG 0537 multicenter randomized study that compared acupuncture-like transcutaneous stimulation (ALTENS) with pilocarpine (PC) for relieving radiation-induced xerostomia.Methods and materialsEligible patients were randomized to twice-weekly 20-minute ALTENS sessions for 24 sessions during 12 weeks or PC (5 mg 3 times daily for 12 weeks). The primary endpoint was the change in the University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS) scores from baseline to 9 months from randomization (MFR). Secondary endpoints included basal and citric acid primed whole salivary production (WSP), ratios of positive responders (defined as patients with ≥20% reduction in overall radiation-induced xerostomia symptom burden), and the presence of adverse events based on the Common Terminology Criteria for Adverse Events version 3. An intention-to-treat analysis was conducted.ResultsOne hundred forty-eight patients were randomized. Only 96 patients completed the required XeQOLS and were evaluable at 9 MFR (representing merely 68.6% statistical power). Seventy-six patients were evaluable at 15 MFR. The median change in the overall XeQOLS in ALTENS and PC groups at 9 and 15 MFR were -0.53 and -0.27 (P=.45) and -0.6 and -0.47 (P=.21). The corresponding percentages of positive responders were 81% and 72% (P=.34) and 83% and 63% (P=.04). Changes in WSP were not significantly different between the groups. Grade 3 or less adverse events, mostly consisting of grade 1, developed in 20.8% of patients in the ALTENS group and in 61.6% of the PC group.ConclusionsThe observed effect size was smaller than hypothesized, and statistical power was limited because only 96 of the recruited 148 patients were evaluable. The primary endpoint-the change in radiation-induced xerostomia symptom burden at 9 MFR-was not significantly different between the ALTENS and PC groups. There was significantly less toxicity

Details

Database :
OAIster
Journal :
International journal of radiation oncology, biology, physics; vol 92, iss 2, 220-227; 0360-3016
Notes :
application/pdf, International journal of radiation oncology, biology, physics vol 92, iss 2, 220-227 0360-3016
Publication Type :
Electronic Resource
Accession number :
edsoai.on1377974279
Document Type :
Electronic Resource